Adhera Therapeutics, Inc. (ATRX)

OTCMKTS: ATRX · Delayed Price · USD
0.800
0.00 (0.00%)
Dec 19, 2022 4:00 PM EST - Market closed
Market Cap 2.53M
Revenue (ttm) n/a
Net Income (ttm) -3.45M
Shares Out 3.16M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 50
Open 0.800
Previous Close 0.800
Day's Range 0.800 - 0.800
52-Week Range 0.600 - 2.600
Beta -0.14
Analysts n/a
Price Target n/a
Earnings Date n/a

About ATRX

Adhera Therapeutics, Inc. focuses on the discovery and development of drugs. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana. [Read more]

Industry Biotechnology
Sector Healthcare
CEO Mr. Andrew Albert Kucharchuk
Employees 2
Stock Exchange OTCMKTS
Ticker Symbol ATRX
Full Company Profile

Financial Performance

Financial Statements

News

Adhera Therapeutics Announces CEO, Senior Management Changes, Plans for NASDAQ Uplist

Baton Rouge, LA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that on September 8...

4 months ago - GlobeNewsWire

Adhera Therapeutics Signs Letter of Intent to Acquire CD71-Targeted Cancer Therapy Paclitaxel Gallium Transferrin

Baton Rouge, LA, July 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that the Company has...

7 months ago - GlobeNewsWire

Adhera Therapeutics Appoints Trond K. Waerness as Chairman of the Board, Company Focuses on Uplist to NASDAQ

Baton Rouge, LA, May 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointmen...

9 months ago - GlobeNewsWire

Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Jean Buteau to Scientific Advisory Board

Baton Rouge, LA, March 21, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointm...

11 months ago - GlobeNewsWire

Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace

Baton Rouge, LA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce its successfu...

1 year ago - GlobeNewsWire

Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders

Baton Rouge, LA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new Ca...

1 year ago - GlobeNewsWire

Adhera Therapeutics Announces Appointment of Dr. Zahed Subhan to Board of Directors

Baton Rouge, LA, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointme...

1 year ago - GlobeNewsWire

Adhera Therapeutics Expands Relationship with Melior Pharmaceuticals I, Adds NASH and Pulmonary Inflammation to Portfolio of Target Indications

Baton Rouge, LA, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that the Company has...

1 year ago - GlobeNewsWire

Manufacturing Commences on Adhera's MLR-1019 for Phase 2a Clinical Trial Treating Parkinson's Disease

IP Estate Grows with New Korean Patent Issued

1 year ago - GlobeNewsWire

7 Biotech Penny Stocks With Huge Catalysts Coming in 2022

With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market. The post 7 Biotech Penny Stocks With Huge Catalysts Coming in 2022 ap...

Other symbols: BLUCYDYDFFNENTX
1 year ago - InvestorPlace

Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias

Baton Rouge, LA, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new Eu...

1 year ago - GlobeNewsWire

Adhera Therapeutics Provides Insight on Corporate Strategy, Development of Parkinson's Disease and Type 1 Diabetes Drugs

Baton Rouge, LA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today provides shareholders an upda...

1 year ago - GlobeNewsWire